Cited by 2,833Heart Failure Treatment and ManagementHeart rate and cardiovascular healthCardiovascular Function and Risk Factors

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

Open access

Cohn, Jay N., Johnson, Gary, Ziesche, Susan, Cobb, Frederick, Francis, Gary, Tristani, Felix, Smith, Raphael, Dunkman, W. Bruce, Loeb, Henry, Wong, Maylene, Bhat, Geetha, Goldman, Steven, Fletcher, Ross D., Doherty, James, Hughes, C. Vincent, Carson, Peter, Cintron, Guillermo, Shabetai, Ralph, Haakenson, Clair·1991·New England Journal of Medicine

DOI 10.1056/nejm199108013250502

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: To define better the efficacy of vasodilator therapy in the treatment of chronic congestive heart failure, we compared the effects of hydralazine and isosorbide dinitrate with those of enalapril in 804 men receiving digoxin and diuretic therapy for heart failure. The patients were randomly assigned in a double-blind manner to receive 20 mg of enalapril daily or 300 mg of hydralazine plus 160 mg of isosorbide dinitrate daily. The latter regimen was identical to that used with a similar patient population in the effective-treatment arm of our previous Vasodilator-Heart Failure Trial. RESULTS: Mortality after two years was significantly lower in the enalapril arm (18 percent) than in the hydralazine-isosorbide dinitrate arm (25 percent) (P = 0.016; reduction in mortality, 28.0 percent), and overall mortality tended to be lower (P = 0.08). The lower mortality in the enalapril arm was attributable to a reduction in the incidence of sudden death, and this beneficial effect was more prominent in patients with less severe symptoms (New York Heart Association class I or II). In contrast, body oxygen consumption at peak exercise was increased only by hydralazine-isosorbide dinitrate treatment (P less than 0.05), and left ventricular ejection fraction, which increased with both regimens during the 2 years after randomization, increased more (P less than 0.05) during the first 13 weeks in the hydralazine-isosorbide dinitrate group. CONCLUSIONS: The similar two-year mortality in the hydralazine-isosorbide dinitrate arms in our previous Vasodilator-Heart Failure Trial (26 percent) and in the present trial (25 percent), as compared with that in the placebo arm in the previous trial, (34 percent) and the further survival benefit with enalapril in the present trial (18 percent) strengthen the conclusion that vasodilator therapy should be included in the standard treatment for heart failure. The different effects of the two regimens (enalapril and hydralazine-isosorbide dinitrate) on mortality and physiologic end points suggest that the profile of effects might be enhanced if the regimens were used in combination.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199108013250502

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,109
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure
Cohn, J. N., Archibald, D. G., Ziesche, S., Franciosa, J. A., Harston, W. E., Tristani, F. E., Dunkman, W. B., Jacobs, W., Francis, G. S., Flohr, K. H., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606123142404 · Cited by 2,400
Self-citation
A placebo-controlled trial of captopril in refractory chronic congestive heart failure
Captopril Multicenter Research Group (1983) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(83)80316-7 · Cited by 588
Vasodilator Therapy of Cardiac Failure
Cohn, J. N., & Franciosa, J. A. (1977) · New England Journal of Medicine · doi:10.1056/nejm197707072970105 · Cited by 483
Self-citation
The role of vasodilator therapy in heart failure
Chatterjee, K., & Parmley, W. W. (1977) · Progress in Cardiovascular Diseases · doi:10.1016/0033-0620(77)90006-8 · Cited by 315
Vasodilator Therapy for Heart Failure
Cohn, J. N. (1973) · Circulation · doi:10.1161/01.cir.48.1.5 · Cited by 293
Self-citation
Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure.
Leier, C. V., Huss, P., Magorien, R. D., & Unverferth, D. V. (1983) · Circulation · doi:10.1161/01.cir.67.4.817 · Cited by 289

Show all 19 references

Research works printed but not linked: 1

Cohn, 1987, Circulation, 76, IV–443

Sorted by citations

Items 501–600 of 1,000

Coronary revascularisation for postischaemic heart failure: how myocardial viability affects survival
Pagano, D., Lewis, M. E., Townend, J., Davies, P., Camici, P. G., & Bonser, R. S. (1999) · Heart · doi:10.1136/hrt.82.6.684 · Cited by 69
A Practical and Evidence-Based Approach to Cardiovascular Disease Risk Reduction
Gluckman, T. J., Baranowski, B. J., Ashen, M. D., Henrikson, C. A., McAllister, M. W., Braunstein, J. B., & Blumenthal, R. S. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.14.1490 · Cited by 69
Differential effects of captopril and enalapril on tissue renin-angiotensin systems in experimental heart failure.
Hirsch, A. T., Talsness, C. E., Smith, A. D., Schunkert, H., Ingelfinger, J. R., & Dzau, V. J. (1992) · Circulation · doi:10.1161/01.cir.86.5.1566 · Cited by 69
Beta-blockers in heart failure: Promising or proved?
Doughty, R. N., MacMahon, S. W., & Sharpe, N. (1994) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(94)90773-0 · Cited by 69
Enfermedad cardiovascular en el anciano
Jackson, C. F., & WENGER, N. K. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.05.001 · Cited by 72
Cardioprotection: definition, classification, and fundamental principles.
Kübler, W., & Haass, M. (1996) · Heart · doi:10.1136/hrt.75.4.330 · Cited by 68
Methods used for the assessment of LV systolic function: common currency or tower of Babel?
Marwick, T. H. (2013) · Heart · doi:10.1136/heartjnl-2012-303433 · Cited by 68
Understanding Heart Failure
Mazurek, J. A., & Jessup, M. L. (2016) · Heart Failure Clinics · doi:10.1016/j.hfc.2016.07.001 · Cited by 75
B-type natriuretic peptide as a marker of the effects of enalapril in patients with heart failure
Yoshimura, M., Mizuno, Y., Nakayama, M., Sakamoto, T., Sugiyama, S., Kawano, H., Soejima, H., Hirai, N., Saito, Y., Nakao, K., et al. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01121-x · Cited by 69
Ramipril
Frampton, J. E., & Peters, D. H. (1995) · Drugs · doi:10.2165/00003495-199549030-00008 · Cited by 68
Transplant candidates with severe left ventricular dysfunction managed with medical treatment: Characteristics and survival
Rickenbacher, P. R., Trindade, P. T., Haywood, G. A., Vagelos, R. H., Schroeder, J. S., Willson, K., Prikazsky, L., & Fowler, M. B. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00587-0 · Cited by 68
Implementing a Congestive Heart Failure Disease Management Program to Decrease Length of Stay and Cost
Knox, D. A., & Mischke, L. (1999) · The Journal of Cardiovascular Nursing · doi:10.1097/00005082-199910000-00007 · Cited by 68
Prognostic value of tomographic rest-redistribution thallium 201 imaging in medically treated patients with coronary artery disease and left ventricular dysfunction
Gioia, G., Milan, E., Giubbini, R., DePace, N. L., Heo, J., & Iskandrian, A. S. (1996) · Journal of Nuclear Cardiology · doi:10.1016/s1071-3581(96)90007-0 · Cited by 68
Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation
Kadish, A. H., Quigg, R. J., SCHAECHTER, I., Anderson, K. P., Estes, M., & Levine, J. H. (2000) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.2000.tb06759.x · Cited by 68
Phenomenon of nitrate tolerance
Mangione, N. J., & Glasser, S. P. (1994) · American Heart Journal · doi:10.1016/0002-8703(94)90020-5 · Cited by 68
Therapy of heart failure
Schrier, R. W., Abdallah, J. G., Weinberger, H. D., & Abraham, W. T. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00986.x · Cited by 68
Direct Vasodilators and Sympatholytic Agents
McComb, M. N., Chao, J. Y., & Ng, T. M. H. (2015) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248415587969 · Cited by 70
Management of Heart Failure in Advancing CKD: Core Curriculum 2018
House, A. A. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.12.006 · Cited by 67
Outcomes by Gender in the African-American Heart Failure Trial
Taylor, A. L., Lindenfeld, J., Ziesche, S., Walsh, M. N., Mitchell, J. E., Adams, K. F., Tam, S. W., Ofili, E., Sabolinski, M. L., Worcel, M., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.06.020 · Cited by 68
Self-citation
Cardiac mechano-electric feedback in man: clinical relevance
Taggart, P. I., & Sutton, P. M. (1999) · Progress in Biophysics and Molecular Biology · doi:10.1016/s0079-6107(98)00039-x · Cited by 67
Enalapril Clinical Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships
MacFadyen, R. J., Meredith, P., & Elliott, H. L. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199325040-00003 · Cited by 69
Early Left Ventricular Dysfunction Elicits Activation of Sympathetic Drive and Attenuation of Parasympathetic Tone in the Paced Canine Model of Congestive Heart Failure
Eaton, G. M., Cody, R. J., Nunziata, E., & Binkley, P. F. (1995) · Circulation · doi:10.1161/01.cir.92.3.555 · Cited by 67
Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition
Hartman, J. C., Hullinger, T. G., Wall, T. M., & Shebuski, R. J. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90958-k · Cited by 67
The causes, consequences, and treatment of left or right heart failure
Peteiro, J., Peteiro-Vázquez, J., Gacía-Campos, A., García‐Bueno, L., Abugattás-de-Torres, J. P., & Castro‐Beiras, A. (2011) · Vascular Health and Risk Management · doi:10.2147/vhrm.s10669 · Cited by 76
Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection
Parmley, W. W. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00208-3 · Cited by 66
Do β-blockers prolong survival in heart failure only by inhibiting the β1-receptor? A perspective on the results of the COMET trial
Packer, M. (2003) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2003.08.003 · Cited by 66
Cardiac resynchronization therapy in patients with heart failure and conduction abnormalities other than left bundle‐branch block: Analysis of the multicenter insync randomized clinical evaluation (MIRACLE)
Aranda, J. M., CONTI, J. B., Johnson, J. W., Petersen‐Stejskal, S., & Curtis, A. B. (2004) · Clinical Cardiology · doi:10.1002/clc.4960271204 · Cited by 66
Molecular Imaging for Efficacy of Pharmacologic Intervention in Myocardial Remodeling
van den Borne, S. W. M., Isobe, S., Zandbergen, H. R., Li, P., Petrov, A. D., Wong, N. D., Fujimoto, S., Fujimoto, A., Løvhaug, D., Smits, J. F. M., et al. (2009) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2008.11.011 · Cited by 65
Pharmacokinetic Drug Interactions with ACE Inhibitors
Shionoiri, H. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199325010-00003 · Cited by 65
Changes in Sinus Node Function in a Rabbit Model of Heart Failure With Ventricular Arrhythmias and Sudden Death
Tobias Opthof, A., Coronel, R., Rademaker, H., VERMEULEN, J. T., Schopman, F. J. G., & Janse, M. J. (2000) · Circulation · doi:10.1161/01.cir.101.25.2975 · Cited by 65
Specialized Centers for Heart Failure Management
Abraham, W. T., & Bristow, M. R. (1997) · Circulation · doi:10.1161/01.cir.96.9.2755 · Cited by 65
The renin-angiotensin system in left ventricular remodeling
Blaufarb, I., & Sonnenblick, E. H. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00183-x · Cited by 65
Synthesis of Some New Pyridazine Derivatives for Anti-HAV Evaluation
Flefel, E. M., Tantawy, W. A., El-Sofany, W. I., El‐Shahat, M., El‐Sayed, A. A., & Abd‐Elshafy, D. N. (2017) · Molecules · doi:10.3390/molecules22010148 · Cited by 64
Lack of long-term ventricular arrhythmia reduction by enalapril in heart failure
Pratt, C. M., Gardner, M. J., Pepine, C. J., Kohn, R. M., Young, J. B., Greenberg, B., Capone, R. J., Kostis, J. B., Henzlova, M. J., Gosselin, G., et al. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80771-1 · Cited by 64
Silent Strokes in Patients With Heart Failure
Siachos, T., VanBakel, A. B., Feldman, D. S., Uber, W. E., Simpson, K. N., & Pereira, N. L. (2005) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2005.04.004 · Cited by 64
Exercise rehabilitation in chronic heart failure
Coats, A. J. S. (1993) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(93)90485-j · Cited by 64
Report of the Task Force on Research in Heart Failure.
Lenfant, C. J. M. (1994) · Circulation · doi:10.1161/01.cir.90.3.1118 · Cited by 64
Medicating race: heart disease and durable preoccupations with difference
Pollock, A. (2013) · Choice Reviews Online · doi:10.5860/choice.50-5029 · Cited by 64
Exploring the dialogism of academic discourse: Heteroglossic Engagement in medical research articles
Fryer, D. L. (2013) · BRILL eBooks · doi:10.1163/9789401209403_011 · Cited by 63
Factors Associated With Racial and Ethnic Diversity Among Heart Failure Trial Participants: A Systematic Bibliometric Review
Wei, S., Le, N., Zhu, J. W., Breathett, K. K., Greene, S. J., Mamas, M. A., Zannad, F. M., & Spall, H. G. C. V. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.008685 · Cited by 64
Management of Heart Failure in the Elderly
Rich, M. W. (2002) · Heart Failure Reviews · doi:10.1023/a:1013706023974 · Cited by 63
The Treatment of Heart Failure: The Role of Neurohumoral Activation.
Middlekauff, H. R., & Mark, A. L. (1998) · Internal Medicine · doi:10.2169/internalmedicine.37.112 · Cited by 63
Use of Nonantiarrhythmic Drugs for Prevention of Sudden Cardiac Death
Alberte, C., & Zipes, D. P. (2003) · Journal of Cardiovascular Electrophysiology · doi:10.1046/j.1540-8167.14.s9.23.x · Cited by 64
Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure.
Kasama, S., Toyama, T., Kumakura, H., Takayama, Y., Ichikawa, S., Suzuki, T., & Kurabayashi, M. (2003) · PubMed · Cited by 63
Heart rate variability in patients with mild to moderate heart failure: Effects of neurohormonal modulation by digoxin and ibopamine
Brouwer, J., van Veldhuisen, D. J., Veld, A. J. M. I. '., Dunselman, P. H. J. M., Boomsma, F., Haaksma, J., & Lie, K. I. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00285-3 · Cited by 63
Validity of claims‐based definitions of left ventricular systolic dysfunction in Medicare patients
Li, Q., Glynn, R. J., Dreyer, N. A., Liu, J., Mogun, H., & Setoguchi, S. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2146 · Cited by 62
Newly detected atrial fibrillation in patients with an implantable cardioverter-defibrillator is a strong risk marker of increased mortality
Bunch, T. J., Day, J. D., Olshansky, B., Stolen, K. Q., & Mullin, C. M. (2008) · Heart Rhythm · doi:10.1016/j.hrthm.2008.09.025 · Cited by 63
Both High and Low HbA1c Predict Incident Heart Failure in Type 2 Diabetes Mellitus
Parry, H., Deshmukh, H., Levin, D., Zuydam, N. V., Elder, D. H. J., Morris, A. D., Struthers, A. D., Palmer, C. N. A., Doney, A. S. F., & Lang, C. C. (2015) · Circulation Heart Failure · doi:10.1161/circheartfailure.113.000920 · Cited by 62
2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter
Heidenreich, P. A., Solis, P., Estes, N. A. M., Fonarow, G. C., Jurgens, C. Y., Marine, J. E., McManus, D. D., & McNamara, R. L. (2016) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/hcq.0000000000000018 · Cited by 62
Heart Failure with Reduced Ejection Fraction in Women
Mentzer, G. G., & Hsich, E. (2018) · Heart Failure Clinics · doi:10.1016/j.hfc.2018.08.003 · Cited by 63
Combination treatment with captopril and the thyroid hormone analogue 3,5-diiodothyropropionic acid. A new approach to improving left ventricular performance in heart failure.
Pennock, G. D., Raya, T. E., Bahl, J. J., Goldman, S., & Morkin, E. (1993) · Circulation · doi:10.1161/01.cir.88.3.1289 · Cited by 62
Self-citation
Predicting and preventing sudden death from cardiac causes.
Gilman, J. K., Jalal, S., & Naccarelli, G. V. (1994) · Circulation · doi:10.1161/01.cir.90.2.1083 · Cited by 62
Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel from the Heart Failure Collaboratory and Academic Research Consortium
Abraham, W. T., Psotka, M. A., Fiuzat, M., Filippatos, G. S., Lindenfeld, J. M., Mehran, R., Ambardekar, A. V., Carson, P. E., Jacob, R., Januzzi, J. L., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2018 · Cited by 65
Self-citation
Twenty-Four-Hour Heart Rate Lowering with Ivabradine in Chronic Heart Failure: Insights from the SHIFT Holter Substudy
Böhm, M., BORER, J. S., Camm, A. J., Ford, I., Lloyd, S. M., Michel Komajda, N., Tavazzi, L., Talajic, M. R., Lainščak, M., Reil, J., et al. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.258 · Cited by 61
The pathophysiology of advanced heart failure
Baig, M. K., Mahon, N., McKenna, W. J., Caforio, A. L. P., Bonow, R. O., Francis, G. S., & Gheorghiade, M. (1999) · Heart & Lung · doi:10.1053/hl.1999.v28.a97762 · Cited by 63
Self-citation
Short Deceleration Time of Mitral Inflow E Velocity: Prognostic Implication with Atrial Fibrillation Versus Sinus Rhythm
Hurrell, D. G., Oh, J. K., Mahoney, D. W., Miller, F. A., & Seward, J. B. (1998) · Journal of the American Society of Echocardiography · doi:10.1016/s0894-7317(98)70025-2 · Cited by 61
Low dose dobutamine stress echocardiography predicts the improvement of left ventricular systolic function in dilated cardiomyopathy
Kitaoka, H., Takata, J., Yabe, T., Hitomi, N., Furuno, T., & Doi, Y. (1999) · Heart · doi:10.1136/hrt.81.5.523 · Cited by 61
Dynamic cardiomyoplasty in South America
Moreira, L. F. P., Stolf, N. A. G., Braile, D. M., & Jatene, A. D. (1996) · The Annals of Thoracic Surgery · doi:10.1016/0003-4975(95)00998-1 · Cited by 61
Management of Heart Failure
Baker, D. W. (1994) · JAMA · doi:10.1001/jama.1994.03520170071039 · Cited by 61
Treatment Performance Measures Affect Clinical Outcomes in Patients With Acute Systolic Heart Failure
Youn, Y. J., Yoo, B., Lee, J., Kim, J., Han, S. W., Jeon, E., Cho, M., Kim, J., Kang, S., Chae, S. C., et al. (2012) · Circulation Journal · doi:10.1253/circj.cj-11-1093 · Cited by 60
Tissue Plasminogen Activator Antigen and D-Dimer as Markers for Atherothrombotic Risk Among Healthy Postmenopausal Women
Pradhan, A. D., LaCroix, A. Z., Langer, R. D., Trevisan, M., Lewis, C. E., Hsia, J. A., Oberman, A., Kotchen, J. M., & Ridker, P. M. (2004) · Circulation · doi:10.1161/01.cir.0000134965.73212.a6 · Cited by 60
Effect of Ramipril in Reducing Sudden Deaths and Nonfatal Cardiac Arrests in High-Risk Individuals Without Heart Failure or Left Ventricular Dysfunction
Teo, K. K., Mitchell, L. B., Pogue, J., Bosch, J., Dagenais, G. R., & Yusuf, S. (2004) · Circulation · doi:10.1161/01.cir.0000141729.01918.d4 · Cited by 60
Comparison of the long term prognostic value of peak exercise oxygen pulse and peak oxygen uptake in patients with chronic heart failure
Solal, A. C., Barnier, P., Pessione, F., Seknadji, P., Logeart, D., Laperche, T., & Gourgon, R. (1997) · Heart · doi:10.1136/hrt.78.6.572 · Cited by 60
Guideline-Directed Medical Therapy for Heart Failure does not Exist: A Non-Judgmental Framework for Describing the Level of Adherence to Evidence-Based Drug Treatments for Patients with a Reduced Ejection Fraction
Packer, M., & Metra, M. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1857 · Cited by 59
Guidelines for management of patients with chronic heart failure in Australia
Krum, H. (2001) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2001.tb143375.x · Cited by 59
Combining salicylate and enalapril in patients with coronary artery disease and heart failure.
Baur, L. H. B., Schipperheyn, J. J., van der Laarse, A., Souverijn, J. H. M., Frölich, M., de Groot, C. P. G. M., Voogd, P. J., Vroom, T. F. F. P., Cats, V. M., & Keirse, M. J. N. C. (1995) · Heart · doi:10.1136/hrt.73.3.227 · Cited by 59
Effects of high-dose lisinopril-isosorbide dinitrate on severe mitral regurgitation and heart failure remodeling
Levine, A. B., Muller, C., & Levine, T. B. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00623-7 · Cited by 58
2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter
Heidenreich, P. A., Solis, P., Estes, N. A. M., Fonarow, G. C., Jurgens, C. Y., Marine, J. E., McManus, D. D., & McNamara, R. L. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.521 · Cited by 58
Plasma norepinephrine and mortality
Cohn, J. N. (1995) · Clinical Cardiology · doi:10.1002/clc.4960181304 · Cited by 58
Self-citation
Arrhythmias in Heart Failure:
Eckardt, L., Haverkamp, W., Johna, R., Böcker, D., Deng, M. C.-H. K., Breithardt, G., & BORGGREEE, M. (2000) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2000.tb00746.x · Cited by 58
Suppressive Effect of the Gly389 Allele of the .BETA.1-Adrenergic Receptor Gene on the Occurrence of Ventricular Tachycardia in Dilated Cardiomyopathy.
Iwai, C., Akita, H., Shiga, N., Takai, E., Miyamoto, Y., Shimizu, M., Kawai, H., Takarada, A., Kajiya, T., & Yokoyama, M. (2002) · Circulation Journal · doi:10.1253/circj.66.723 · Cited by 58
Renal and Electrolyte Complications of Congestive Heart Failure and Effects of Therapy With Angiotensin-Converting Enzyme Inhibitors
Oster, J. R. (1992) · Archives of Internal Medicine · doi:10.1001/archinte.1992.00400160022006 · Cited by 58
Calcium channel blockers in heart failure
Elkayam, U., Shotan, A., Mehra, A., & Ostrzega, E. (1993) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(93)90478-j · Cited by 58
Treatment of Systemic Hypertension in Patients With Pulmonary Disease
Dart, R. A., Gollub, S., Lazar, J., Nair, C. K., Schroeder, D. P., & Woolf, S. H. (2003) · CHEST Journal · doi:10.1378/chest.123.1.222 · Cited by 58
Clinical profiles of four large pedigrees with familial dilated cardiomyopathy
Crispell, K. A., Wray, A., Ni, H., Nauman, D. J., & Hershberger, R. E. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00276-4 · Cited by 58
Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure.
Yoshimura, M., Yasue, H., Tanaka, H., Kikuta, K., Sumida, H., Katô, H., Jougasaki, M., & Nakao, K. (1994) · Heart · doi:10.1136/hrt.72.6.528 · Cited by 58
Perioperative angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing mortality and morbidity in adults
Zou, Z., Yuan, H., Yang, B., Xu, F., Chen, X. Y., Liu, G. J., & Shi, X. Y. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009210.pub2 · Cited by 57
Initial Experience With an Implantable Hemodynamic Monitor
Steinhaus, D. M., Lemery, R., Bresnahan, D. R., Handlin, L. R., Bennett, T., Moore, A., Cardinal, D., Foley, L., & Levine, R. (1996) · Circulation · doi:10.1161/01.cir.93.4.745 · Cited by 57
Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure
Ward, R. E., Gheorghiade, M., Young, J. B., & Uretsky, B. F. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00140-u · Cited by 57
Medical management of pediatric heart failure
Ahmed, H., & VanderPluym, C. J. (2021) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-20-358 · Cited by 58
The Use of Left Ventricular Ejection Fraction in the Diagnosis and Management of Heart Failure. A Clinical Consensus Statement of the Heart Failure Association (HFA) of the ESC, the Heart Failure Society of America (HFSA), and the Japanese Heart Failure Society (JHFS)
Rosano, G. M. C., Teerlink, J. R., Kinugawa, K., Bayés‐Genís, A., Chioncel, O. D., Fang, J. C.-T., Greenberg, B., Ibrahim, N. E., Imamura, T., Inomata, T., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3646 · Cited by 60
Usefulness of Isosorbide Dinitrate and Hydralazine as Add-on Therapy in Patients Discharged for Advanced Decompensated Heart Failure
Müllens, W., Abrahams, Z., Francis, G. S., Sokos, G. G., Starling, R. C., Young, J. B., Taylor, D. O., & Tang, W. H. W. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.12.028 · Cited by 56
Self-citation
Feasibility study of the use of the TandemHeart® percutaneous ventricular assist device for treatment of cardiogenic shock
Burkhoff, D., O’Neill, W. W., Brunckhorst, C., Letts, D. P., Lasorda, D., & Cohen, H. A. (2006) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.20796 · Cited by 56
Long-term continuous external electrocardiographic recording: a review
Enseleit, F., & Duru, F. (2006) · EP Europace · doi:10.1093/europace/euj054 · Cited by 60
Angiotensin-converting enzyme inhibitors.
Menard, J., & Patchett, A. (2001) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(01)56002-7 · Cited by 30
Amiodarone and torsades de pointes in patients with advanced heart failure
Middlekauff, H. R., Stevenson, W. G., Saxon, L. A., & Stevenson, L. W. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80138-6 · Cited by 56
Rationale, design, and methods for a pivotal randomized clinical trial for the assessment of a cardiac support device in patients with New York health association class III-IV heart failure
Mann, D. L., Acker, M. A., Jessup, M. L., Sabbah, H. N., Starling, R. C., & Kubo, S. H. (2004) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2003.10.007 · Cited by 56
Natural history of idiopathic dilated cardiomyopathy: effect of referral bias and secular trend
Redfield, M. M., Gersh, B. J., Bailey, K. R., Ballard, D., & Rodeheffer, R. J. (1993) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(93)90780-5 · Cited by 56
Heart Failure: A Class Review of Pharmacotherapy.
Shah, A. A., Gandhi, D., Srivastava, S., Shah, K. J., & Mansukhani, R. P. (2017) · PubMed Central · Cited by 55
Investigating pyridazine and phthalazine exchange in a series of iridium complexes in order to define their role in the catalytic transfer of magnetisation from para-hydrogen
Appleby, K. M., Mewis, R. E., Olaru, A. M., Green, G. G. R., Fairlamb, I. J. S., & Duckett, S. B. (2015) · Chemical Science · doi:10.1039/c5sc00756a · Cited by 55
Survival after myocardial revascularization for ischemic cardiomyopathy: A prospective ten-year follow-up study
Shah, P. J., Hare, D. L., Raman, J., Gordon, I. J., Chan, R. K. M., Horowitz, J. D., Rosalion, A., & Buxton, B. F. (2003) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(03)00809-2 · Cited by 55
Translational Success Stories: Angiotensin Receptor 1 Antagonists in Heart Failure
Dell’Italia, L. J. (2011) · Circulation Research · doi:10.1161/circresaha.110.238550 · Cited by 55
CSI position statement on management of heart failure in India
Guha, S., Harikrishnan, S., Ray, S., Sethi, R., Ramakrishnan, S., Banerjee, S., Bahl, V. K., Goswami, K. C., Banerjee, A. K., Shanmugasundaram, S., et al. (2018) · Indian Heart Journal · doi:10.1016/j.ihj.2018.05.003 · Cited by 59
The Pharmacoeconomics of ACE Inhibitors in Chronic Heart Failure
McMurray, J. J. V., & Davie, A. P. (1996) · PharmacoEconomics · doi:10.2165/00019053-199609030-00002 · Cited by 55
Persistent hemodynamic improvement with short-term nitrate therapy in patients with chronic congestive heart failure already treated with captopril
Mehra, A., Ostrzega, E., Shotan, A., Johnson, J. V., & Elkayam, U. (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)90767-s · Cited by 55
Quality of Life and Prognosis in Heart Failure: Results of the Beta-Blocker Evaluation of Survival Trial (BEST)
Tate, C. W., Robertson, A. D., Zolty, R., Shakar, S. F., Lindenfeld, J. M., Wolfel, E. E., Bristow, M. R., & Lowes, B. D. (2007) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2007.07.001 · Cited by 55
Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients
Griffith, T. F., Chua, B. S. Y., Allen, A. S., Klassen, P., Reddan, D. N., & Szczech, L. A. M. (2003) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2003.08.028 · Cited by 55
Differential Regulation of Cardiac Angiotensin Converting Enzyme Binding Sites and AT1Receptor Density in the Failing Human Heart
Zisman, L. S., Asano, K., Dutcher, D. L., Ferdensi, A., Robertson, A. D., Jenkin, M. J., Bush, E. W., Bohlmeyer, T. J., Perryman, M. B., & Bristow, M. R. (1998) · Circulation · doi:10.1161/01.cir.98.17.1735 · Cited by 55
Getting the Numbers Right: Statistical Mischief and Racial Profiling in Heart Failure Research
Kahn, J. (2003) · Perspectives in biology and medicine · doi:10.1353/pbm.2003.0087 · Cited by 55
Current medical therapy for advanced heart failure
Gheorghiade, M., Cody, R. J., Francis, G. S., McKenna, W. J., Young, J. B., & Bonow, R. O. (1998) · American Heart Journal · doi:10.1016/s0002-8703(98)70253-4 · Cited by 55
Self-citation

Authors: Cohn, J. N., Johnson, G., Ziesche, S., Cobb, F., Francis, G., Tristani, F., Smith, R., Dunkman, W. B., Loeb, H., Wong, M., Bhat, G., Goldman, S., Fletcher, R. D., Doherty, J., Hughes, C. V., Carson, P., Cintron, G., Shabetai, R., & Haakenson, C.
Affiliations: University of Minnesota (US)
ORCID: Cohn, Jay N.
Johnson, Gary
Bhat, Geetha
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1991-08
Volume: 325
Issue: 5
Pages: 303-310
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199108013250502
OpenAlex: W2046383587
Cited by: 2,833
References: 19
Citations by year: 2026: 14 · 2025: 15 · 2024: 26 · 2023: 21 · 2022: 31 · 2021: 27 · 2020: 46 · 2019: 39 · 2018: 51 · 2017: 56 · 2016: 69 · 2015: 59 · 2014: 54 · 2013: 61 · 2012: 56
FWCI: 124.25
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords: enalapril, hydralazine, isosorbide dinitrate, chronic congestive heart failure, vasodilator therapy, mortality, sudden death, exercise oxygen consumption, left ventricular ejection fraction, ACE inhibitors, combination therapy, digoxin, diuretics, NYHA functional class
MeSH terms: Adolescent, Adult, Aged, Chronic Disease, Death, Sudden, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Enalapril, Physical Exertion, Heart Failure, Hospitalization, Humans, Hydralazine, Isosorbide Dinitrate, Male, Middle Aged, Norepinephrine, Oxygen Consumption, Patient Compliance, Stroke Volume, Survival Rate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks